Dolly Vance compensation by year
RIGEL PHARMACEUTICALS Summary Compensation Table · all 5 fiscal years held| Component | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 |
|---|---|---|---|---|---|
| Salary | $489,814 | $489,814 | $504,508 | $514,598 | $524,890 |
| Bonus | $0 | $0 | $0 | $0 | $0 |
| Stock awards | $0 | $0 | $0 | $0 | $0 |
| Option awards | $493,380 | $393,545 | $863,124 | $420,682 | $459,869 |
| Non-equity incentive | $159,190 | $244,907 | $401,402 | $239,288 | $200,770 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 | $0 |
| All other | $1,794 | $1,794 | $1,794 | $7,394 | $9,054 |
| Total | $1,144,178 | $1,130,060 | $1,770,828 | $1,181,962 | $1,194,583 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: RIGEL PHARMACEUTICALS INC DEF 14A filed April 6, 2021, accession 0001104659-21-047180, and prior-year filings. Open the filing on EDGAR.
How this page was built: the RIGEL PHARMACEUTICALS INC filed document, accession 0001104659-21-047180. Every figure is read from that document and cited to the page and table it appears in. Filed April 6, 2021.
Equity holdings
unvested awards at FY2020 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| Option | 67,253 | — | $2.42 |
| Option | 37,500 | — | $2.42 |
| Option | 37,500 | — | $2.42 |
| Option | 75,000 | — | $2.42 |
| Option | 45,247 | — | $2.42 |
| Option | 40,624 | — | $2.00 |
| Option | 40,626 | — | $2.00 |
| Option | 15,229 | — | $4.49 |
| Option | 22,271 | — | $4.49 |
Per the Outstanding Equity Awards at Fiscal Year-End table in RIGEL PHARMACEUTICALS INC's FY2020 proxy; value at the fiscal year-end close, as the company printed it.
RIGEL PHARMACEUTICALS’s named executive officers, FY2020
as the company reported each| Named executive officer | Role | FY2020 total |
|---|---|---|
| Raul Rodriguez | President and Chief Executive Officer | $2,963,884 |
| Dean Schorno | Executive Vice President and Chief Financial Officer | $1,202,524 |
| Dolly Vance · this page | Executive Vice President, Corporate Affairs, General | $1,194,583 |
| David Santos | Executive Vice President and Chief Commercial Officer | $1,190,602 |
| Wolfgang Dummer | Executive Vice President and Chief Medical Officer | $730,439 |
The full RIGEL PHARMACEUTICALS compensation record
free company briefThis page is one person within RIGEL PHARMACEUTICALS's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the RIGEL PHARMACEUTICALS proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are RIGEL PHARMACEUTICALS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.